Gpr37 (Park7) Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
GPR37 (G protein-coupled receptor 37), also known as PAELR (PARKIN-associated endothelin receptor-like 1), is a highly conserved GPCR predominantly expressed in the central nervous system. This receptor has garnered significant attention in neurodegeneration research due to its direct interaction with PARKIN, an E3 ubiquitin ligase mutated in familial Parkinson's disease. GPR37-expressing neurons represent a specific population critical to understanding dopaminergic neuron survival and the pathogenesis of Parkinson's disease. [1]
The GPR37 gene (also designated as GPR37L1 or PAELR) encodes a GPCR belonging to the class A rhodopsin family. Key molecular features include: [2]
GPR37 exhibits unique pharmacological properties: [3]
GPR37-expressing neurons are localized to key brain regions: [4]
GPR37 neurons participate in several critical circuits: [5]
GPR37 modulates dopaminergic neuron function through: [6]
A critical function involves the unfolded protein response (UPR): [7]
GPR37 promotes neuron survival through:
GPR37 is directly implicated in PD pathogenesis:
Genetic links:
Pathogenic mechanisms:
Therapeutic implications:
GPR37 research utilizes:
Current drug development focuses on:
](/cell-types/substantia-nigra-pars-compacta-dopamine-neurons
--alpha-synuclein-pathway
--protein-quality-control-in-neurodegeneration)## External Links
The study of Gpr37 (Park7) Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Zhang et al. GPR37 dysfunction in dopaminergic neurons (2023). 2023. ↩︎
Wang et al. ER stress and neurodegeneration in GPR37 mutants (2023). 2023. ↩︎
Kelm et al. GPR37 as a therapeutic target in Parkinson's disease (2022). 2022. ↩︎
Zhang et al. GPR37 and alpha-synuclein aggregation (2022). 2022. ↩︎
Yang et al. GPR37 knockout mice phenotype (2021). 2021. ↩︎
Liu et al. GPR37 polymorphisms and PD risk (2021). 2021. ↩︎
Thompson et al. GPR37 chaperone therapy (2020). 2020. ↩︎